COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
A phase 1/2 trial of Durvalumab, Oleclumab, FOLFOX in colorectal cancer, run by MedImmune LLC, active and no longer recruiting.
Overview
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC is a phase 1/2 interventional study registered as NCT04068610 by MedImmune LLC, with 61 participants enrolled, started 2019-09-13 and due to reach its primary completion in 2022-10-10. Interventions recorded: Durvalumab, Oleclumab, FOLFOX, Bevacizumab. Conditions listed: Metastatic Microsatellite-stable Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small
Shares Oleclumab, Durvalumab, AstraZeneca.
- TrialA Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Durvalumab, Bevacizumab, AstraZeneca.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Durvalumab, Bevacizumab, AstraZeneca.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, Bevacizumab, AstraZeneca.
- TrialA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Shares Oleclumab, Durvalumab, AstraZeneca.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Oleclumab, AstraZeneca.
- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Durvalumab, Bevacizumab, AstraZeneca.
- TrialA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Shares Oleclumab, AstraZeneca.